抗ST6 Gal Sialyltransferase 1/ST6GAL1/CD75 (LN-1) - Bioreactor Concentrate抗体 | Anti-ST6 Gal Sialyltransferase 1/ST6GAL1/CD75 (LN-1) - Bioreactor Concentrate Antibody

• 価格
• Image
• Background

価格

目次に戻る

Image

Immunohistochemistry-Paraffin: CD75 Antibody (LN-1) [NBP2-29466] - Formalin-fixed, paraffin-embedded normal human spleen tissue stained with CDw75 antibody (1:500), peroxidase-conjugate and DAB chromogen. Note the cell membrane/cytoplasmic staining. Immunohistochemical staining of formalin/paraffin tissues is enhanced by unmasking of the target epitope by boiling the tissue sections in 10mM citrate buffer, pH 6.0, for 10 min followed by cooling at room temp for 20 min.

Flow Cytometry: CD75 Antibody (LN-1) [NBP2-29466] - Surface staining of 10^6 human lymphocytes with 25 ul of CDw75 antibody (red) and 1 ug of isotype control (green, 20113A). PPI negative population analysed.

目次に戻る

Background

CDw75 (also known as CD75s) is an alpha (2,6)-sialylated neuraminidase-sensitive lymphocyte cell surface differentiation antigen synthesized by the ST6Gal 1 enzyme (Bast, 1992; Kumar, 2012). CDw75 was characterized in 1989 at the 4th Leucocyte Typing Workshop (code number LN1) as an antigen or differentiation marker expressed by the majority of B cells. The LN-1 CDw75 antibody clone is a well-established B lymphocyte marker and detects CDw75 on germinal center B lymphocytes and leukemias/lymphomas and other tissues (Epstein, 1984). The antibody is highly published and widely recognized as a reliable and robust CDw75 antibody for identifying or confirming a B cell phenotype in known lymphoid tissues. Overall, the analysis of lymphocyte populations in human lymphoid tissues is greatly facilitated by using antibody markers against lymphoid differentiation antigens such as CDw75. The CDw75 antibody may be used in of itself or as part of an antibody panel to localize lymphocyte subsets in the lymph node, spleen, and thymus as well as for immunophenotypic characterization of malignancies. However, it is important to note that CD molecules like CDw75 are typically not strictly specific for a single hematopoietic lineage and a considerable number are not leukocyte restricted (Moller, 1991). In this regard, CDw75 is also expressed on a large spectrum of nonlymphoid cells (reviewed in Epstein, 1984 & Moller, 1991). The spectrum of CDw75 antibody reactivity includes RBC precursors of bone marrow, epithelium of kidney, breast, prostate, pancreas, and lung, glioblastomas, astrocytomas, colon carcinomas and Reed-Sternberg cells in Hodgkin's lymphoma. The activity of ST6Gal 1, the enzyme that synthesizes CDw75, may be modified during carcinogenesis and be associated with emergence of the CDw75 antigen. For example, CDw75 was found to be expressed in a subset of colon carcinomas but not in healthy disease-free nor in inflammatory colorectal mucosa (Costa-Noguiera, 2009; Villar-Portela, 2011). These results suggested that the CDw75 antibody may also be a useful antibody marker of tumor progression and malignant potential in certain solid tumors (Costa-Noguiera, 2009; Villar-Portela, 2011).

目次に戻る